HR
LRMR icon

Howe & Rusling’s Larimar Therapeutics LRMR Stock Holding History

Howe & Rusling’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2
Closed -$1K – 1037
2015
Q3 		$1K Hold
2
– – ﹤0.01% 930
2015
Q2 		$1K Buy
+2
New +$837 ﹤0.01% 964

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Howe & Rusling's LRMR Position: Q4 2015 in Review

Howe & Rusling sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 2 shares — an estimated $1K sold.

Howe & Rusling first reported a position in LRMR in Q2 2015 and held it in 2 quarters. The position peaked at $1K in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Howe & Rusling reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Howe & Rusling sold 2 Larimar Therapeutics shares in Q4 2015, an estimated $1K.
  • Howe & Rusling first reported a position in Larimar Therapeutics in Q2 2015 and held it in 2 quarters.
  • Howe & Rusling's Larimar Therapeutics position peaked at $1K in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Howe & Rusling's 13F filing for Q4 2015, filed 11 Feb 2016.